Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
742 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bladder Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2016, provides an overview of the Bladder Cancer (Oncology) pipeline landscape. Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Bladder Cancer. Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 7 Bladder Cancer Overview 8 Therapeutics Development 9 Bladder Cancer - Therapeutics under Development by Companies 11 Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 19 Bladder Cancer - Pipeline Products Glance 20 Bladder Cancer - Products under Development by Companies 23 Bladder Cancer - Products under Investigation by Universities/Institutes 34 Bladder Cancer - Companies Involved in Therapeutics Development 35 Bladder Cancer - Therapeutics Assessment 144 Drug Profiles 167 Bladder Cancer - Dormant Projects 693 Bladder Cancer - Discontinued Products 703 Bladder Cancer - Product Development Milestones 704 Appendix 721
List of Tables Number of Products under Development for Bladder Cancer, H2 2016 29 Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016 30 Number of Products under Development by Companies, H2 2016 31 Number of Products under Development by Companies, H2 2016 (Contd..1) 32 Number of Products under Development by Companies, H2 2016 (Contd..2) 33 Number of Products under Development by Companies, H2 2016 (Contd..3) 34 Number of Products under Development by Companies, H2 2016 (Contd..4) 35 Number of Products under Development by Companies, H2 2016 (Contd..5) 36 Number of Products under Development by Companies, H2 2016 (Contd..6) 37 Number of Products under Development by Companies, H2 2016 (Contd..7) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 39 Comparative Analysis by Late Stage Development, H2 2016 40 Comparative Analysis by Clinical Stage Development, H2 2016 41 Comparative Analysis by Early Stage Development, H2 2016 42 Products under Development by Companies, H2 2016 43 Products under Development by Companies, H2 2016 (Contd..1) 44 Products under Development by Companies, H2 2016 (Contd..2) 45 Products under Development by Companies, H2 2016 (Contd..3) 46 Products under Development by Companies, H2 2016 (Contd..4) 47 Products under Development by Companies, H2 2016 (Contd..5) 48 Products under Development by Companies, H2 2016 (Contd..6) 49 Products under Development by Companies, H2 2016 (Contd..7) 50 Products under Development by Companies, H2 2016 (Contd..8) 51 Products under Development by Companies, H2 2016 (Contd..9) 52 Products under Development by Companies, H2 2016 (Contd..10) 53 Products under Investigation by Universities/Institutes, H2 2016 54 Bladder Cancer - Pipeline by 4SC AG, H2 2016 55 Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 56 Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2016 57 Bladder Cancer - Pipeline by Agenus Inc, H2 2016 58 Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2016 59 Bladder Cancer - Pipeline by AndroScience Corporation, H2 2016 60 Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2016 61 Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016 62 Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2016 63 Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 64 Bladder Cancer - Pipeline by Aura Biosciences, Inc., H2 2016 65 Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 66 Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016 67 Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 68 Bladder Cancer - Pipeline by Bayer AG, H2 2016 69 Bladder Cancer - Pipeline by BioCancell Ltd, H2 2016 70 Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 71 Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 72 Bladder Cancer - Pipeline by Biotest AG, H2 2016 73 Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74 Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 75 Bladder Cancer - Pipeline by Celgene Corporation, H2 2016 76 Bladder Cancer - Pipeline by Cellceutix Corporation, H2 2016 77 Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 78 Bladder Cancer - Pipeline by Celprogen, Inc., H2 2016 79 Bladder Cancer - Pipeline by Celsion Corporation, H2 2016 80 Bladder Cancer - Pipeline by Codagenix, Inc., H2 2016 81 Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2016 82 Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 83 Bladder Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2016 84 Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2016 85 Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2016 86 Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc., H2 2016 87 Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2016 88 Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2016 89 Bladder Cancer - Pipeline by enGene, Inc, H2 2016 90 ancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 91 Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 93 Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016 94 Bladder Cancer - Pipeline by Gene Signal International SA, H2 2016 95 Bladder Cancer - Pipeline by Genmab A/S, H2 2016 96 Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 97 Bladder Cancer - Pipeline by H3 Biomedicine Inc., H2 2016 98 Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2016 99 Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2016 100 Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2016 101 Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 102 Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 103 Bladder Cancer - Pipeline by ImmuNext, Inc., H2 2016 104 Bladder Cancer - Pipeline by Immunocore Limited, H2 2016 105 Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2016 106 Bladder Cancer - Pipeline by Immupharma Plc, H2 2016 107 Bladder Cancer - Pipeline by InteRNA Technologies B.V., H2 2016 108 Bladder Cancer - Pipeline by Johnson & Johnson, H2 2016 109 Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H2 2016 110 Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2016 111 Bladder Cancer - Pipeline by MaxiVAX SA, H2 2016 112 Bladder Cancer - Pipeline by Meabco A/S, H2 2016 113 Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H2 2016 114 Bladder Cancer - Pipeline by MedImmune LLC, H2 2016 115 Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2016 116 Bladder Cancer - Pipeline by Merck KGaA, H2 2016 117 Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2016 118 Bladder Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 119 Bladder Cancer - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 120 Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2016 121 Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016 122 Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2016 123 Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2016 124 Bladder Cancer - Pipeline by Omeros Corporation, H2 2016 125 Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016 126 Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 127 Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016 128 Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 129 Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2016 130 Bladder Cancer - Pipeline by Pfizer Inc., H2 2016 131 Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2016 132 Bladder Cancer - Pipeline by Philogen S.p.A., H2 2016 133 Bladder Cancer - Pipeline by Plexxikon Inc., H2 2016 134 Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 135 Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 136 Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016 137 Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 138 Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H2 2016 139 Bladder Cancer - Pipeline by Sanofi, H2 2016 140 Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 141 Bladder Cancer - Pipeline by Serometrix, LLC, H2 2016 142 Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016 143 Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016 144 Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 145 Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 146 Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2016 147 Bladder Cancer - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 148 Bladder Cancer - Pipeline by Synovo GmbH, H2 2016 149 Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 150 Bladder Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 151 Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2016 152 Bladder Cancer - Pipeline by Telormedix SA, H2 2016 153 Bladder Cancer - Pipeline by TesoRx Pharma LLC, H2 2016 154 Bladder Cancer - Pipeline by Theravectys SA, H2 2016 155 Bladder Cancer - Pipeline by Theryte Limited, H2 2016 156 Bladder Cancer - Pipeline by Transgene SA, H2 2016 157 Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 158 Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2016 159 Bladder Cancer - Pipeline by Vault Pharma Inc., H2 2016 160 Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2016 161 Bladder Cancer - Pipeline by Vaxiion Therapeutics, Inc., H2 2016 162 Bladder Cancer - Pipeline by Viralytics Ltd., H2 2016 163 Assessment by Monotherapy Products, H2 2016 164 Assessment by Combination Products, H2 2016 165 Number of Products by Stage and Target, H2 2016 167 Number of Products by Stage and Mechanism of Action, H2 2016 175 Number of Products by Stage and Route of Administration, H2 2016 184 Number of Products by Stage and Molecule Type, H2 2016 186 Bladder Cancer - Dormant Projects, H2 2016 713 Bladder Cancer - Dormant Projects (Contd..1), H2 2016 714 Bladder Cancer - Dormant Projects (Contd..2), H2 2016 715 Bladder Cancer - Dormant Projects (Contd..3), H2 2016 716 Bladder Cancer - Dormant Projects (Contd..4), H2 2016 717 Bladder Cancer - Dormant Projects (Contd..5), H2 2016 718 Bladder Cancer - Dormant Projects (Contd..6), H2 2016 719 Bladder Cancer - Dormant Projects (Contd..7), H2 2016 720 Bladder Cancer - Dormant Projects (Contd..8), H2 2016 721 Bladder Cancer - Dormant Projects (Contd..9), H2 2016 722 Bladder Cancer - Discontinued Products, H2 2016 723
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
